FluoGuide enters agreement with Swedish university hospital for the second phase of the ongoing FG001 clinical trial (correction)

Correction: The subject line in e-mail recipients contained a wrong text. No other corrections. Copenhagen, Denmark, 30 June 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the Company has entered into an agreement with the Department of Neurosurgery, Linköping University Hospital, Sweden to become the second site investigating FG001´s effect in guiding surgical removal of aggressive brain cancer. Linköping University Hospital is added to the second phase of the ongoing clinical phase I/II trial.

The release as fetched from its publisher. fluoguide.com ↗